Results 181 to 190 of about 8,967,918 (378)

Transitional Care Programme Evaluation – The Singapore Experience

open access: yesInternational Journal of Integrated Care, 2013
Patsy Chow, Loong Mun Wong, Jason Cheah
doaj   +3 more sources

Four Health Care Organizations' Efforts to Improve Patient Care and Reduce Costs [PDF]

open access: yes, 2012
Synthesizes findings from four case studies in the Brookings-Dartmouth ACO Pilot Program about forming integrated systems that can deliver accountable care under shared-savings agreements with private ...
Aricca D. Van Citters   +8 more
core  

Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma

open access: yesMolecular Oncology, EarlyView.
The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.
Jenifer Brea‐Iglesias   +12 more
wiley   +1 more source

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

Healthcare Hot Spotting: Variation in Quality and Resource Use In California [PDF]

open access: yes, 2015
This Issue Brief presents analyses of data available through the HEDIS by Geography tool, accessible at https://hbg.iha.org. The tool allows users to display and compare measures of both quality of care and use of health care resources throughout ...
Dolores Yanagihara   +2 more
core  

Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis

open access: yesMolecular Oncology, EarlyView.
TRIM24 and TRIM28 are androgen receptor (AR) coregulators which exhibit increased expression with cancer progression. Both TRIM24 and TRIM28 combine to influence the response of castrate‐resistant prostate cancer (CRPC) cells to AR inhibitors by mediating AR signalling, regulation of MYC and upregulating VEGF to promote angiogenesis. Castrate‐resistant
Damien A. Leach   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy